FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Epcoritamab Breakthrough Status in Follicular Lymphoma

[ Price : $8.95]

FDA grants Genmab a breakthrough therapy designation for epcoritamab, an investigational T-cell engaging bispecific antibody admin...

BD Recalls Pumps Over Syringe Incompatibility

[ Price : $8.95]

Becton Dickinsons Carefusion unit recalls (Class 1) its Alaris Infusion Pumps due to compatibility issues with Cardinal Health Mon...

FDA Checking Chinese Syringe Safety

[ Price : $8.95]

FDA says it is evaluating possible safety issues with some plastic syringes manufactured by several firms in China.

Chief Scientist Tapped as Woodcock Replacement

[ Price : $8.95]

FDA commissioner Robert Califf names agency chief scientist Namandj Bumpus as the replacement for retiring principal deputy commis...

More Novo Nordisk Semaglutide Legal Actions

[ Price : $8.95]

Novo Nordisk says it is seeking legal action against two compounding pharmacies it says are selling adulterated and misbranded dru...

AbbVie Seeks Accelerated OK for Lung Cancer Drug

[ Price : $8.95]

Based on new clinical study data, AbbVie says it will seek accelerated approval for telisotuzumab-vedotin in patients with c-Met p...

Info Collection on Combination Product Jurisdiction

[ Price : $8.95]

Federal Register notice: FDA sends to OMB an information collection extension entitled Product Jurisdiction and Combination Produc...

UCB on Pregnancy Safety Studies

[ Price : $8.95]

UCB makes suggestions for FDA to consider in developing a framework to optimize post-approval pregnancy safety studies.

FDA Clears GE Critical Care Suite 2.1

[ Price : $8.95]

FDA clears GE Healthcares Critical Care Suite 2.1 that includes a pneumothorax algorithm.

Arcturus Therapeutics Orphan Status for ARCT-032

[ Price : $8.95]

FDA grants Arcturus Therapeutics an orphan drug designation for ARCT-032 and its use to treat cystic fibrosis.